Nikhil Prasad Fact checked by:Thailand Medical News Team Aug 06, 2024 4 months, 2 weeks, 5 days, 7 hours ago
Cancer Updates: Introduction to Non-Receptor Tyrosine Kinases
Cancer research has unveiled numerous mechanisms that drive tumor progression and resistance to treatments. Among these, Non-Receptor Tyrosine Kinases (NRTKs) play a pivotal role. These enzymes, located inside cells rather than on their surface, act as switches to turn various cellular functions on or off. This
Cancer Updates news report explores how targeting NRTKs could lead to breakthrough cancer therapies.
Structure of non-receptor tyrosine kinase families and their functional domains. Non-receptor tyrosine kinases (NRTKs) including Ack, Jak, Fes, Fak, Tec, Src, Csk, Abl, and Syk kinases.NRTKs consist of a single protein with N- and C-terminal regions. The N-terminus contains a kinase domain, which extends over approximately 300 residues, while the N-terminus of NRTKs is larger than the N-terminus. The structure and the functional domains and regions of different members of NRTKs include the following: Src homology (SH) domains that are referred to as SH4, SH3, SH2, and catalytic SH1 domains, the Pleckstrin homology (PH), four-point-one, ezrin, radixin, moesin (FERM), the Janus homology 2 (JH2) domain, and the Fes/Fer/Cdc-42-interacting protein homology (FCH) domains, Bruton's tyrosine kinase (Btk)-like zinc finger, the coiled-coil motifs (CC), and proline-rich region (pr). The Cdc42/Rac-interactive (CRIB) domains, DNA-binding domains (DNA), action-binding domain, and a focal adhesion targeting domain (FAT)
Researchers from George Washington University-USA, LSU Health Sciences Center-USA, Heinrich-Heine University Duesseldorf-Germany, and other esteemed institutions have highlighted the significance of NRTKs in cancer. Their study delves into the structure, function, and potential therapeutic targeting of these enzymes, offering new hope in the fight against cancer.
What Are Non-Receptor Tyrosine Kinases?
NRTKs are enzymes that regulate cell growth, division, and survival. Unlike receptor tyrosine kinases (RTKs) that span the cell membrane, NRTKs are found within the cell, mainly in the cytoplasm and sometimes in the nucleus. Their main function is to phosphorylate proteins, a process crucial for cellular signaling.
The study identifies several key NRTKs, including Ack, Jak, Fes, Fak, Tec, Src, Csk, Abl, and Syk kinases. These enzymes are often overactive in cancer cells, making them prime targets for new treatments. By understanding their structure and mechanisms, researchers aim to develop drugs that can specifically inhibit these kinases and stop cancer progression.
The Structure and Function of NRTKs
Each NRTK has a unique structure that determines its function. For instance, the Ack family of kinases includes Ack1 and Tnk1, which have domains such as the sterile alpha motif (SAM) and the clathrin-binding motif. These domains are crucial for their activation and function.
Ack1, in particular, has been shown to
play a significant role in cancer by promoting cell invasion and migration. It phosphorylates proteins that are involved in cell adhesion, making it easier for cancer cells to spread. Understanding the structure of Ack1 helps researchers design inhibitors that can block its activity and prevent metastasis.
Key Findings in NRTK Research
The study sheds light on several important findings:
Ack1 and Cancer Metastasis: Ack1 promotes tumor cell invasion and migration by phosphorylating key proteins involved in cell adhesion. Inhibiting Ack1 could prevent the spread of cancer cells to other parts of the body.
Jak Kinases in Immune Response: Jak family kinases are critical for cytokine signaling, which impacts immune cell function. Their abnormal activation is linked to cancer progression, making them attractive targets for therapy. Inhibitors of Jak kinases could modulate immune responses to fight cancer more effectively.
Fes Kinases in Hematopoietic Cancers: Fes kinases, originally derived from viral oncogenes, play a role in blood cell formation and function. Their activation is linked to certain blood cancers, and targeting Fes kinases could provide new treatment options for these diseases.
Fak Kinases in Cell Survival: Fak family kinases are involved in cell adhesion and survival. Overexpression of Fak is associated with aggressive cancers. Inhibitors of Fak kinases could disrupt these processes, leading to reduced tumor growth.
Tec Kinases in Immune Regulation: Tec family kinases, such as Btk and Itk, are essential for immune cell signaling. They play a role in regulating immune responses, and targeting these kinases could enhance the body’s ability to fight cancer.
Src Kinases in Multiple Cancers: Src family kinases are versatile regulators of cell functions like proliferation and migration. Their activation is linked to various cancers. Src inhibitors are being developed to target these kinases and inhibit tumor growth.
Csk Kinases as Tumor Suppressors: Csk family kinases act as negative regulators of Src kinases. Enhancing Csk activity could suppress tumor growth and provide a new therapeutic approach.
Abl Kinases in Leukemia and Beyond: Abl kinases, including Abl and Arg, are well-known for their role in leukemia. Their involvement in solid tumors is also significant, and targeting Abl kinases could benefit patients with various cancers.
Syk Kinases: A Dual Role: Syk kinases can act as both tumor suppressors and promoters, depending on the context. Modulating Syk activity offers a complex but promising therapeutic strategy.
Therapeutic Potential of NRTKs
Targeting NRTKs holds immense potential for developing new cancer therapies. Inhibitors that block the activity of these kinases could prevent tumor growth and overcome resistance to existing treatments. For example, Ack1 inhibitors could stop cancer cells from spreading, while Jak inhibitors could modulate immune responses to better fight tumors.
Moreover, the study emphasizes the importance of personalized medicine. By understanding the specific NRTKs involved in an individual’s cancer, treatments can be tailored to target those kinases, improving the effectiveness of therapy and reducing side effects.
Conclusion: A New Era in Cancer Treatment
The comprehensive analysis of NRTKs reveals their critical roles in cancer progression and resistance to treatment. By targeting these enzymes, researchers hope to develop more effective cancer therapies. The study underscores the need for ongoing research and clinical trials to bring these promising treatments to patients.
The study findings were published in the peer-reviewed journal: Cancers.
https://www.mdpi.com/2072-6694/16/15/2754
For the latest
Cancer Updates, keep on logging to Thailand Medical News.
Read Also:
https://www.thailandmedical.news/news/formononetin-from-astragalus-provides-new-hope-against-multidrug-resistant-cancers
https://www.thailandmedical.news/news/iron-driven-cell-death-could-combat-ebv-linked-tumors
